Introduction {#s1}
============

Hepatitis A and hepatitis B are amongst the most common infectious diseases worldwide [@pone.0071124-Ott1], [@pone.0071124-Wasley1]. Superinfection with hepatitis A virus (HAV) or hepatitis B virus (HBV) in patients with underlying chronic liver disease is associated with a higher risk of morbidity and mortality [@pone.0071124-Almasio1], [@pone.0071124-Keeffe1], [@pone.0071124-Liaw1]. Both HAV and HBV infections are preventable by highly effective and safe vaccines [@pone.0071124-Andre1], [@pone.0071124-Innis1], [@pone.0071124-Szmuness1], [@pone.0071124-Zuckerman1]. Experts have recommended screening for susceptibility to HAV and HBV infection and vaccination against them for all patients with chronic liver disease [@pone.0071124-Keeffe2], [@pone.0071124-Lau1]. The CDC and several professional societies have also recommended vaccination against HAV and HBV for susceptible patients with chronic liver disease. In 2008, Centers for Medicare and Medicaid Services (CMS) proposed HAV and HBV vaccination for eligible patients with chronic hepatitis C infection (HCV) as a quality measure [@pone.0071124-Fiore1], [@pone.0071124-Mast1], [@pone.0071124-Mast2], [@pone.0071124-Pham1].

Prior studies have demonstrated shortcomings in adherence to vaccination guidelines in specific subgroups of patients with chronic liver disease in the United States and around the world. In a study of patients with chronic hepatitis C infection in a Veterans Administration Healthy System in California, an adherence rate of 71% for HAV and 70% for HBV and 62% for both vaccination was found [@pone.0071124-Hernandez1]. Similarly, in a large cohort of HCV patients from the Department of Veterans Affairs quality measure of HAV and HBV vaccination or documentation of immunity were met in just 57% and 45.5% patients, respectively [@pone.0071124-Kramer1]. A study of patients with autoimmune hepatitis from Germany found vaccination rates of just 11% for HBV and 13% for HAV [@pone.0071124-Worns1].

Given the increased focus on preventive care and advent of pay for performance models of health care delivery, it likely that adherence to vaccination guideline will be emphasized as a quality measure. Low adherence to vaccination guidelines in primary care settings has been documented [@pone.0071124-Jacobs1]. However, limited data are available on whether specialists that care for chronic liver disease patients perform better on these quality measures than community physicians [@pone.0071124-Jacobs1]. Furthermore, it is also unknown whether adoption of electronic health records (EHR) and introduction of CMS-mandated quality measures reporting has affected physician practice patterns in terms of adhering to hepatitis vaccination guidelines.

Therefore, the objectives of this study were: (1) To evaluate adherence to hepatitis vaccination guidelines in patients with chronic liver disease at a tertiary care hepatology clinic, (2) to identify barriers to vaccinations in patients with chronic liver disease, and (3) to determine physician variability in adherence to vaccination guidelines.

Methods {#s2}
=======

Study setting {#s2a}
-------------

This study was approved by the University of Pittsburgh Medical Center (UPMC) Quality Improvement Committee and the Institutional Review Board waived the need for written informed consent from the participants. The study was conducted at the Center for Liver Diseases (CLD) of the UPMC-Presbyterian Hospital (PUH). PUH is an 800-bed, level 1, fully accredited regional trauma center and the primary teaching hospital of the University of Pittsburgh School of Medicine where residents and fellows train in a wide variety of medical specialties and sub-specialties. The CLD is the outpatient clinic for evaluation and management of patients with liver diseases referred to PUH. The CLD is staffed by 6--8 hepatologists, 3 advanced practice providers, 6--8 nurses, and 8--10 nurse's aides and medical assistants and 100% of the clinic's practice is focused on liver diseases.

Study cohort {#s2b}
------------

We reviewed medical records of all new patients (n = 820) who were evaluated at the UPMC liver clinic in the year 2008 to identify the study population for this study. Patients were eligible if they had chronic liver disease that meets criteria for vaccination for hepatitis A and B, and had a minimum of two follow-up visits during the subsequent 12 months. Patients with chronic hepatitis B (as suggested by positive Hepatitis B surface antigen (HBsAg) were excluded. Therefore, the final study cohort consisted of 705 patients.

Data Collection {#s2c}
---------------

A detailed chart review (including paper records from referring physicians) was performed for all patients who formed the final study cohort to collect information on demographics, referral source, etiology of chronic liver disease, presence of cirrhosis, evidence of decompensation, primary CLD provider, whether serological testing for HAV (hepatitis A antibody \[total\]) and HBV (HBsAg, hepatitis B surface antibody \[HBsAb\], hepatitis B core antibody \[HBcAb\]) was performed (prior to or at the CLD), results of HAV and HBV serology, whether a patient received vaccination prior to CLD referral, whether vaccination was recommended in eligible patients at the CLD, and barriers to vaccination in patients in whom vaccination was recommended at the CLD but who did not get vaccinated. Patients who were recommended but did not receive vaccination were contacted by telephone by one of the investigators (KT) to determine the reason(s). Patients that could not contacted to confirm their vaccination status were categorized as having unknown vaccination status.

In 2008, CMS introduced HAV and HBV vaccination as a PQRI measure for Medicare patients with chronic HCV infection. This PQRI measure was incorporated in the CLD clinical workflow in the form of an electronic reminder window that was activated as soon as the provider chose chronic HCV as a diagnosis for a Medicare patient. Providers were required to complete the PQRI questionnaire before the electronic chart could be closed for billing. To determine whether vaccination recommendation rates differed based on Medicare status of the patients, we electronically retrieved information on whether a patient had Medicare insurance at any point during the year 2008.

Definition of eligibility for vaccination {#s2d}
-----------------------------------------

For hepatitis A, patients who had a negative HAV antibody were considered eligible for vaccination. For hepatitis B, patients who were negative for HBs antigen, HBs antibody and HBc antibody were considered eligible. Since there are no specific guidelines for vaccination in patients with isolated HBc antibody, we excluded these patients for evaluation of vaccination adherence.

Statistical analysis {#s2e}
--------------------

Descriptive analyses are presented as proportions for categorical data, and as median and interquartile range (IQR) for continuous data. Univariate analysis for categorical data was performed using the chi-squared or Fisher's exact test as appropriate and, for continuous variables, using Mann-Whitney-U test. Data analysis was performed using SPSS software version 19 (SPSS Inc., Chicago, Ill., USA). Two-tailed *p*-values \<0.05 were considered significant.

Results {#s3}
=======

[Table 1](#pone-0071124-t001){ref-type="table"} shows data on demographics, referral source, etiology, presence of cirrhosis and insurance status of the 705 patients who formed the final study cohort. About half of the subjects were male, predominantly white and were most frequently referred by either their primary physician or gastroenterologist. Over 80% patients had a single etiology for their chronic liver disease. The most common etiologies were hepatitis C, nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH) and alcohol. Cirrhosis was present in 39.1% patients and approximately one third of cirrhotics had decompendated disease at the time of evaluation.

10.1371/journal.pone.0071124.t001

###### Demographics, etiology and disease status of the study population (N = 705).

![](pone.0071124.t001){#pone-0071124-t001-1}

  Variable                                                            
  ------------------------------------------------------------------- -------------
  Age (years) -- median (IQR)                                          53 (44, 60)
  Male gender -- n (%)                                                 373 (52.9)
  Race -- n (%)                                                       
  White                                                                604 (85.7)
  Black                                                                 80 (11.3)
  Other/Unknown                                                         21 (3.0)
  Referral Source -- n (%)                                            
  Primary Care Physician                                               403 (57.2)
  Gastroenterologist                                                   116 (16.5)
  Other Physicians                                                      75 (10.6)
  Unknown                                                              111 (15.7)
  Number of etiologies -- n (%)                                       
  One                                                                  587 (83.3)
  Two                                                                  111 (15.7)
  More than two                                                          7 (1.0)
  Etiology -- n (%)?                                                  
  Hepatitis C                                                          347 (49.2)
  Alcohol                                                              122 (17.3)
  NAFLD/NASH                                                           199 (28.2)
  PBC                                                                   33 (4.7)
  PSC                                                                   29 (4.1)
  Autoimmune Hepatitis                                                  46 (6.5)
  Hereditary Hemachromatosis                                            10 (1.4)
  Hepatocellular Carcinoma                                               7 (1.0)
  Other Liver tumors                                                     4 (0.6)
  Others                                                                33 (4.7)
  Cirrhosis -- n (%)                                                   276 (39.1)
  Decompensated Cirrhosis -- n (%)[\*](#nt104){ref-type="table-fn"}     99 (35.9)

IQR -- interquartile range.

ˆTotal is more than 705 due to overlap of etiologies.

NAFLD -- nonalcoholic fatty liver disease; NASH -- nonalcoholic steatohepatitis; PBC -- Primary biliary cirrhosis; PSC -- Primary sclerosing cholangitis.

Proportion among patients with cirrhosis.

Testing for Hepatitis A and B status {#s3a}
------------------------------------

HAV antibody was tested in 619/705 (87.7%) patients either prior to or at the CLD. Of these, 183/619 (29.5%) tested positive for HAV antibody ([Table 2](#pone-0071124-t002){ref-type="table"}). There were no differences between patients who did and did not have HAV testing based on demographics, referral source, distribution and type of etiology, decompensated cirrhosis and Medicare status.

10.1371/journal.pone.0071124.t002

###### Number of new patients with chronic liver disease tested for Hepatitis A and B immunity before or at the liver clinic in the year 2008.

![](pone.0071124.t002){#pone-0071124-t002-2}

  Variable              Before Center for Liver Diseases Visit N (%)   At Center for Liver Diseases N (%)   Before or at Center for Liver Diseases N (%)
  -------------------- ---------------------------------------------- ------------------------------------ ----------------------------------------------
  Hepatitis A                                                                                              
  Antibody tested                        102 (14.5)                                541 (76.7)                                619 (87.8)
  Antibody positive                      24 (23.5)                                 166 (30.6)                                183 (29.5)
  Hepatitis B                                                                                              
  HBs antigen tested                     198 (28.1)                                507 (71.9)                                637 (90.4)
  HBs antibody                                                                                             
   Tested                                125 (17.7)                                 522 (74)                                 596 (84.5)
   Positive                              32 (25.6)                                 154 (29.5)                                176 (29.5)
  HBc antibody                                                                                             
   Tested                                109 (15.5)                                524 (74.3)                                591 (83.8)
   Positive                              24 (22.0)                                 94 (17.9)                                 111 (18.8)

HAV vaccine received before patient seen at Center for Liver Diseases --47 (6.7).

HBV vaccine received before patient seen at Center for Liver Diseases --67 (9.5).

HBs antigen, HBs antibody and HBc antibody were tested either before or at the CLD in 90.4% (637/705), 84.5% (596/705) and 83.8% (591/705) patients, respectively ([Table 2](#pone-0071124-t002){ref-type="table"}). Of the patients tested, 29.5% were positive for HBs antibody, and 18.8% were positive for HBc antibody. Patients with etiologies other than hepatitis C were more likely to be tested for HBs antigen (92.7% vs. 87.9%, p = 0.03) and those with primary biliary cirrhosis (97% vs. 83.2%, p = 0.03) were more likely to be tested for HBc antibody. Otherwise, there were no differences between patients who did or did not have testing for HBV serology.

Eligibility for vaccination for Hepatitis A and B at CLD {#s3b}
--------------------------------------------------------

After excluding patients who were HAV antibody positive (n = 183) or had received HAV vaccination before referral to the CLD (n = 47; in 25 of these a positive HAV antibody following vaccination was documented), 411 patients were eligible for HAV vaccination at the CLD ([Figure 1](#pone-0071124-g001){ref-type="fig"}). After excluding patients who were positive for HBs antibody positive, HBc antibody positive or received HBV vaccination before referral to the CLD (n = 67), 375 patients were eligible for HBV vaccination at CLD ([Figure 1b](#pone-0071124-g001){ref-type="fig"}). Patients in whom the serological status for HAV and HBV was unknown (i.e. they did not undergo testing for HAV and/or HBV) were excluded from consideration of eligibility for vaccination.

![Flowcharts showing how often new patients with chronic liver disease were tested for, eligible for, and were recommended hepatitis vaccination in the liver clinic.\
A) Hepatitis A vaccination. \*Patients not eligible for HAV vaccination included those with positive HAV antibody or who reported completion of the HAV vaccination series. B) HBV vaccination. \*Patients not eligible for HBV vaccination included those who had a positive HBs antibody and/or positive HBc antibody or who reported completion of the HBV vaccination series.](pone.0071124.g001){#pone-0071124-g001}

Patients who were eligible to receive vaccination for HAV and HBV were more likely to be white and have NAFLD/NASH or etiology other than hepatitis C ([Tables 3](#pone-0071124-t003){ref-type="table"} and [4](#pone-0071124-t004){ref-type="table"}). While patients eligible to receive HAV vaccination were more likely to be younger, have no cirrhosis and have insurance other than Medicare; those eligible for HBV vaccination were more likely to be older, have cirrhosis and Medicare insurance ([Table 3](#pone-0071124-t003){ref-type="table"}). The proportion of patients who were eligible for vaccination for HAV and HBV were similar across six providers at the CLD (data not shown).

10.1371/journal.pone.0071124.t003

###### Eligibility for Hepatitis A vaccination among 619 new chronic liver disease patients and the proportion where it was recommended at the liver clinic.

![](pone.0071124.t003){#pone-0071124-t003-3}

  Variable (N)                                   Eligible for Vaccination N (%)     p-value     Vaccine Recommended N (%)   p-value
  --------------------------------------------- -------------------------------- ------------- --------------------------- ---------
  Overall (619)                                            411 (66.3)                 \-                259 (63)              \-
  Age (years) -- median (IQR)                                                                                              
  Yes (eligible/recommended)                              53 (43, 59)             **\<0.001**          53 (42, 60)           0.23
  No (not eligible/not recommended)                       56 (44, 63)                                  52 (43, 58)         
  Gender                                                                                                                   
  Male (327)                                               209 (63.9)                0.17              139 (66.5)            0.15
  Female (292)                                             202 (69.2)                                  120 (59.4)          
  Race                                                                                                                     
  White (532)                                              371 (69.7)             **\<0.001**          232 (62.5)            0.34
  Non White (78)                                            32 (41)                                     23 (71.9)          
  Hepatitis C                                                                                                              
  Yes (298)                                                174 (58.4)             **\<0.001**          104 (59.8)            0.26
  No (321)                                                 237 (73.8)                                  155 (65.4)          
  Alcoholic liver disease                                                                                                  
  Yes (108)                                                72 (66.7)                   1                43 (59.7)            0.59
  No (511)                                                 338 (66.3)                                  216 (63.7)          
  NAFLD/NASH[\*](#nt107){ref-type="table-fn"}                                                                              
  Yes (172)                                                 129 (75)               **0.006**            78 (60.5)            0.51
  No (447)                                                 282 (63.1)                                  181 (64.2)          
  Cirrhosis                                                                                                                
  Yes (250)                                                148 (59.2)              **0.002**            95 (64.2)            0.75
  No (369)                                                 263 (71.3)                                  164 (62.4)          
  Decompensated cirrhosis                                                                                                  
  Yes (87)                                                 53 (60.9)                 0.18               28 (52.8)            0.049
  No (161)                                                  95 (59)                                     67 (70.5)          
  Number of etiologies                                                                                                     
  One (512)                                                344 (67.2)                0.36              218 (63.4)            0.74
  More than one (107)                                      67 (62.6)                                    41 (61.2)          
  Medicare enrolleê                                                                                                        
  Yes (165)                                                99 (60.0)               **0.043**            68 (68.7)            0.19
  No (446)                                                 307 (68.8)                                  187 (60.9)          

NAFLD -- nonalcoholic fatty liver disease; NASH -- nonalcoholic steatohepatitis.

ˆMedicare enrollee at anytime during 2008; information missing in 8 patients.

\% for eligible patients is based on the number of overall patients.

\% for vaccine recommended is based on the number of patients eligible for vaccination.

10.1371/journal.pone.0071124.t004

###### Eligibility for Hepatitis B vaccination among 637 new chronic liver disease patients and the proportion where it was recommended at the liver clinic.

![](pone.0071124.t004){#pone-0071124-t004-4}

  Variable (N)                                   Eligible for Vaccination N (%)     p-value     Vaccine Recommended N (%)   p-value
  --------------------------------------------- -------------------------------- ------------- --------------------------- ---------
  Overall (637)                                            375 (58.9)                 \-               224 (59.7)             \-
  Age (years) -- median (IQR)                                                                                              
  Yes (eligible/recommended)                              55 (46, 63)             **\<0.001**          55 (45, 63)           0.56
  No (not eligible/not recommended)                       52 (40, 58)                                  54 (46, 61)         
  Gender                                                                                                                   
  Male (338)                                               192 (56.8)                0.29              116 (60.4)            0.83
  Female (299)                                             183 (61.2)                                  108 (59.0)          
  Race                                                                                                                     
  White (545)                                              345 (63.3)             **\<0.001**          207 (60.0)              1
  Non White (82)                                           22 (26.8)                                    13 (59.1)          
  Hepatitis C                                                                                                              
  Yes (305)                                                125 (41.0)             **\<0.001**           67 (53.6)             0.1
  No (332)                                                 250 (75.3)                                  157 (62.8)          
  Alcoholic liver disease                                                                                                  
  Yes (111)                                                74 (66.7)                 0.07               38 (51.4)            0.11
  No (526)                                                 301 (57.2)                                  186 (61.8)          
  NAFLD/NASH[\*](#nt111){ref-type="table-fn"}                                                                              
  Yes (175)                                                123 (70.3)             **\<0.001**           69 (56.1)            0.37
  No (462)                                                 252 (54.5)                                  155 (61.5)          
  Cirrhosis                                                                                                                
  Yes (251)                                                170 (67.7)             **\<0.001**          102 (60.0)              1
  No (386)                                                 205 (53.1)                                  122 (59.5)          
  Decompensated cirrhosis                                                                                                  
  Yes (93)                                                  67 (72)                  0.33               35 (52.2)            0.11
  No (156)                                                 102 (65.4)                                   67 (65.7)          
  Number of etiologies                                                                                                     
  One (532)                                                310 (58.3)                0.52              190 (61.3)            0.21
  More than one (105)                                      65 (61.9)                                    34 (52.3)          
  Medicare enrolleê                                                                                                        
  Yes (165)                                                110 (66.7)              **0.02**             72 (66.5)            0.16
  No (463)                                                 261 (56.4)                                  149 (57.1)          

NAFLD -- nonalcoholic fatty liver disease; NASH -- nonalcoholic steatohepatitis.

ˆMedicare enrollee at anytime during 2008; information missing in 9 patients.

\% for eligible patients is based on the number of overall patients.

\% for vaccine recommended is based on the number of patients eligible for vaccination.

Vaccination recommendation for Hepatitis A and B at CLD {#s3c}
-------------------------------------------------------

In eligible patients, vaccination for HAV and HBV was recommended at the CLD in only 63% and 59.7%, respectively ([Tables 3](#pone-0071124-t003){ref-type="table"} and [4](#pone-0071124-t004){ref-type="table"}). While hepatitis A vaccination was recommended more often in eligible patients with no decompensated cirrhosis, the recommendation for HBV vaccination was not dependent on demographics, referral source, distribution and type of etiology, decompensated cirrhosis and Medicare status.

We found significant variability when we analyzed the data by individual providers ([Figure 2](#pone-0071124-g002){ref-type="fig"}). Recommendation for vaccination in eligible patients ranged from 32.4% to 98.6% for hepatitis A and 30% to 89.6% for hepatitis B. When we limited the analyses to patients who had Hepatitis C and Medicare at any point during the study period, the results for vaccination recommendations overall and by provider were similar (data not shown).

![Recommendation for vaccination in eligible patients stratified by liver clinic providers for A) Hepatitis A and B) Hepatitis B.](pone.0071124.g002){#pone-0071124-g002}

### Barriers to vaccination {#s3c1}

Among the 259 patients in whom HAV vaccination was recommended at the CLD, 177 (68.3%) underwent vaccination, 3 (1.2%) had partial vaccination (insurance changed in 1, lost in 1 and no specific reason in 1), 38 (14.7%) did not undergo vaccination, and the status of vaccination was unknown in the remaining 41 (15.8%) patients. The reasons for not getting vaccination (n = 38) were: no clear reason (24), were on other medications (hydroxychloroquine and infliximab in one each), PCP's office did not have vaccines or did not give it (4), no prescription given or did not know where to get the vaccine (3), no insurance coverage (3), lost script (1), and did not have PCP (1).

Discussion {#s4}
==========

Our study makes several important contributions to the literature. First, we demonstrate that adherence to HAV and HBV vaccination guidelines in a specialty hepatology clinic, while higher than rates reported in community-based practices, is far from optimal. Second, we show that significant variability in adherence to vaccination guidelines exists amongst providers within the same practice. Third, we find that an EHR-based electronic reminder system did not improve vaccination recommendation rates. Finally, we find that insurance is not a major impediment to vaccination but lack of adequate counseling and patient education may be a factor in patient compliance with vaccination recommendations.

In the current healthcare climate, there is increased focus on preventive care as a key intervention to provide the most cost-effective care [@pone.0071124-Woolf1]. We found that just 30% of patients were immune to HAV and HBV infection prior to referral to the liver clinic. Our results are similar to a previous study, which reported that vaccination recommendation rates in primary care clinics were lower than in specialty clinics [@pone.0071124-Jacobs1]. Thus, increasing awareness of hepatitis vaccination among primary care physicians is another strategy to potentially improve vaccination rates in patients with chronic liver disease. Surprisingly, we found that insurance was a barrier to vaccination in only a small number of patients [@pone.0071124-Keeffe3]. We speculate that inadequate explanation or counseling for the need for vaccination may be one potential source for noncompliance with vaccination recommendation. It is likely that this noncompliance may be amenable to approaches such as patient educational material or involvement of nursing staff or advanced practitioners in the process.

Recent studies have highlighted variations in quantifiable outcomes and adherence to well-established guidelines amongst primary care physicians as well as specialists [@pone.0071124-Barclay1], [@pone.0071124-Chamie1], [@pone.0071124-Prevedello1], [@pone.0071124-Sherman1]. Given that the demographic, etiological, and clinical characteristics of patients were similar between the providers, the observed variability in vaccination recommendations cannot be explained by these patient-specific factors. We did not measure the characteristics of individual physicians that correlated with adherence to vaccination guidelines but further research is warranted to elucidate these variables.

In our clinic, a "pop-up" electronic reminder was activated for every Medicare patients with a billing diagnosis of HCV infection and providers could not sign-off on these charts without addressing specific questions about these patients\' hepatitis vaccination status. While there was a small financial incentive associated with complying with the PQRI queries, there was no penalty associated with noncompliance. We found no difference in vaccine recommendation rates between this cohort of Medicare patients and the rest of the patient population. Future prospective studies will be needed to address the question whether such EHR-based reminder systems can improve compliance with vaccination guidelines.

Several limitations of this study should be noted. First, this was a retrospective study that was performed at a single center. Second, we did not record characteristics of individual physicians or practice pattern differences between physicians and their advanced practice providers that might explain the individual variability in vaccination recommendation rates. Third, since EHR-based reminders were only required during the study period for Medicare patients with hepatitis C infection, our results on automated computerized reminders may not be generalizable to other etiologies and groups of patients.

In summary, we show here that adherence to hepatitis vaccination guidelines, while higher than reported in community-based clinics, was low even in an academic hospital-based hepatology clinic. Furthermore, there were significant variations amongst providers, which did not correlate with the number of patients seen by individual physicians, within the same practice in adhering to vaccination guidelines in eligible patients. Finally, most patients who were recommended vaccination but failed to get them offered no specific reason for their noncompliance, highlighting the need for better education and counseling of patients with regard to this important preventive intervention.
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